Fast Five Quiz: Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)

Karl J. D'Silva, MD


June 23, 2020

Chronic lymphocytic leukemia (CLL) is one of the most common hematologic cancers and can be accompanied by potentially serious comorbidities, such as venous thromboembolism, anemia, and hypertension.

A majority of patients diagnosed with CLL respond well to first-line treatment. But, given the pathophysiology of CLL, recurrence is inevitable for many. Fortunately, treatment for relapsed/refractory CLL has significantly improved in recent years, with data showing prolonged progression-free survival in this population.

Do you know the basics about relapsed/refractory CLL?


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as: